Back

The wearable cardioverter-defibrillator: current technology and evolving indications

EP Europace Journal

4 October 2016
Organised by: Logo
Read full article
ESC Journals

Abstract

The wearable cardioverter-defibrillator has been available for over a decade and now is frequently prescribed for patients deemed at high arrhythmic risk in whom the underlying pathology is potentially reversible or who are awaiting an implantable cardioverter-defibrillator. The use of the wearable cardioverter-defibrillator is included in the new 2015 ESC guidelines for the management of ventricular arrhythmias and prevention of sudden cardiac death. The present review provides insight into the current technology and an overview of this approach.

ESC 365 is supported by

novartis Explore sponsored resources